HCA Healthcare Inc

HCA Healthcare Inc(HCA)股票分析

$469.030

+1.735 (+0.37%)收盤時

Loading chart…
最高
473.460
開盤
465.760
成交量加權均價
468.09
成交量
1.03M
市值
89.91B
最低
461.770
成交金額
480.70M
企業價值/稅息折舊攤銷前利潤(TTM)
9.44

HCA Healthcare, Inc. is a health care services company. The Company provides acute care hospitals, ambulatory surgery centers (ASCs), freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, radiation and oncology therapy centers, comprehensive rehabilitation and physical therapy centers, hospices, and various other facilities. Its general, acute care hospitals provide a full range of services to accommodate such medical specialties as internal medicine, general surgery, cardiology, oncology, neurosurgery, orthopedics and obstetrics, as well as diagnostic and emergency services. Its behavioral hospitals provide a full range of mental health care services through inpatient, partial hospitalization and outpatient settings. It operates approximately 190 hospitals comprised of 179 general acute care hospitals, seven behavioral hospitals, and four rehabilitation hospitals and its facilities are in 19 states and the United Kingdom.

AI 分析 of HCA Healthcare Inc (HCA)

買進

HCA Healthcare Inc is a good buy right now, trading at $469.03, with a forward P/E of 13.85, indicating it is undervalued compared to its earnings potential. The recent analyst ratings show optimism, with BMO Capital giving an Outperform rating and a price target of $495, suggesting a potential upside of 5.55%. However, insider selling has increased by 1487.91%, which could be a concern for potential investors.

分析師評級(22)

上檔空間 +4.87%
買進
16 買進
6 持有
0 賣出
目前: 469.03
最低
420.00
平均
491.89
最高
525.00

TD Cowen

2026-10-12

目標價

$460

買進

RBC Capital

2026-10-07

目標價

$496

優於大盤

BMO Capital

2026-09-22

目標價

$495

優於大盤

JPMorgan

2026-08-20

目標價

$425

中性

BofA

2026-08-10

目標價

$425

中性

估值指標

HCA Healthcare Inc(HCA)目前預期本益比為 13.85,5 年平均預期本益比為 14.01。

預期本益比

合理
5 年均值 P/E
14.01
目前P/E
13.85
高估
15.51
低估
12.52

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
9.04
目前EV/EBITDA
9.44
高估
9.64
低估
8.45

預期股價營收比

合理
5 年均值 P/S
1.16
目前P/S
1.27
高估
1.30
低估
1.03

Alphio AI 對 HCA 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%HCA

$444.76

情境價格

基

基準

基準 · 50%HCA

$443.49

情境價格

悲

悲觀

悲觀 · 25%HCA

$394.94

情境價格

持有 HCA 的大戶

L

LGT Fund Management Company AG

+ 持有HCA

+9.63%

3個月報酬率

C

Campbell & Company, LP

+ 持有HCA

+9.56%

3個月報酬率

T

Towers Watson Investment Management Limited

+ 持有HCA

+9.42%

3個月報酬率

C

Cbus Industry Superannuation Fund

+ 持有HCA

+7.89%

3個月報酬率

D

Darsana Capital Partners LP

+ 持有HCA

+7.37%

3個月報酬率

C

Consulta Ltd.

+ 持有HCA

+7.15%

3個月報酬率

HCA 常見問題 —— 由 Alphio AI 解答

HCA Healthcare, Inc. is a health care services company. The Company provides acute care hospitals, ambulatory surgery centers (ASCs), freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, radiation and oncology therapy centers, comprehensive rehabilitation and physical therapy centers, hospices, and various other facilities. Its general, acute care hospitals provide a full range of services to accommodate such medical specialties as internal medicine, general surgery, cardiology, oncology, neurosurgery, orthopedics and obstetrics, as well as diagnostic and emergency services. Its behavioral hospitals provide a full range of mental health care services through inpatient, partial hospitalization and outpatient settings. It operates approximately 190 hospitals comprised of 179 general acute care hospitals, seven behavioral hospitals, and four rehabilitation hospitals and its facilities are in 19 states and the United Kingdom. It operates in the Healthcare sector (SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC industry).

HCA Healthcare Inc is a good buy right now, trading at $469.03, with a forward P/E of 13.85, indicating it is undervalued compared to its earnings potential. The recent analyst ratings show optimism, with BMO Capital giving an Outperform rating and a price target of $495, suggesting a potential upside of 5.55%. However, insider selling has increased by 1487.91%, which could be a concern for potential investors.

22 analysts cover HCA: 16 rate it Buy, 6 Hold and 0 Sell. The average price target is 491.89.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易